The University of Virginia Center for Diabetes Technology and Tandem Diabetes Care, Inc. have entered into a multi-year collaboration agreement to advance research and development efforts on fully automated insulin delivery systems. This partnership will build on the UVA Center for Diabetes Technology’s innovative work in improving care for diabetes patients through technology-based interventions, as well as Tandem’s expertise in insulin delivery devices and data management.
The goal of the collaboration is to enhance care and quality of life for diabetes patients around the world by expanding research efforts into automated insulin delivery. Scientists, clinicians, and experts from both institutions will work together on this project, with the potential for clinical research to accelerate the approval of Tandem’s next-generation automated insulin delivery systems.
John Sheridan, president and CEO of Tandem, expressed optimism about the collaboration, citing past successful research projects with UVA that have contributed to life-changing products for people with diabetes. Tandem will provide research funding, technology, and supplies to the University of Virginia for diabetes-centered research and potential clinical studies.
This collaboration represents an exciting new chapter in the long-standing partnership between UVA and Tandem, with the shared goal of delivering new innovations that can improve the lives of people living with diabetes. The research conducted as part of this agreement has the potential to have a significant impact on the treatment and management of diabetes worldwide.
Source
Photo credit cvillerightnow.com